XML 136 R29.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Three months ended March 31,
20252024
Revenue$1,764 $1,532 
Less:
Research and development employee expense, lab supplies and overhead4,436 7,100 
Imdusiran IM-PROVE I, II & III clinical trials expense2,384 5,389 
AB-101-001 Phase 1a/1b clinical trial expense1,899 2,810 
Other early research and development programs expense240 104 
General and administrative expense5,832 5,312 
Restructuring expense12,373 — 
Other segment expense (1)
323 237 
Add:
Interest income1,197 1,545 
Segment net loss$(24,526)$(17,875)
Adjustments and reconciling items— — 
Consolidated net loss$(24,526)$(17,875)
(1) Other segment expense includes the change in the fair value of contingent consideration, non-cash interest expenses and foreign currency exchange gains and losses.